Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Recursion Pharmaceuticals Inc (RXRX) USD0.00001 A

Sell:$30.35 Buy:$30.42 Change: $2.01 (6.21%)
Market closed |  Prices as at close on 30 July 2021 | Switch to live prices |
Sell:$30.35
Buy:$30.42
Change: $2.01 (6.21%)
Market closed |  Prices as at close on 30 July 2021 | Switch to live prices |
Sell:$30.35
Buy:$30.42
Change: $2.01 (6.21%)
Market closed |  Prices as at close on 30 July 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company uses Recursion Operating System (Recursion OS), a multi-layer system for generating, analyzing and deriving insights from biological and chemical datasets. It consists of three parts: Infrastructure Layer, The Recursion Data Universe and The Recursion Map. Its programs include REC-4881, REC-3599, REC-2282, REC-994, lead molecules for the treatment of C. difficile Colitis, lead molecules for the treatment of Neuroinflammation, lead molecules for the treatment of Batten Disease and lead molecules for the treatment of CMT2A.

Contact details

Address:
41S RIO GRANDE STREET
SALT LAKE CITY
84101
United States
Telephone:
+1 (385) 2690203
Website:
https://www.recursionpharma.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
RXRX
ISIN:
US75629V1044
Market cap:
$5.49 billion
Shares in issue:
168.32 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Tina Larson
    President, Chief Operating Officer
  • Michael Secora
    Chief Financial Officer
  • Heather Kirkby
    Chief People Officer
  • Benjamin Mabey
    Chief Technology Officer
  • Sharathchandra Hegde
    Chief Scientific Officer
  • Louisa Daniels
    Chief Legal Officer, General Counsel
  • Ramona Doyle
    Chief Medical Officer
  • Mason Victors
    Chief Product Officer
  • Shafique Virani
    Chief Corporate Development Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.